Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

International arbitration counsel for multinational consumer products corporation in major insurance recovery actions
The firm served as lead counsel in representing a major multinational corporation headquartered in Switzerland in two related international more
Milliken & Company v. Interface, Inc., et al.
The firm served as lead counsel on behalf of Interface Inc., a leading manufacturer of carpet tile, in patent litigation filed by one of its largest more
Acquisition of Dubai-based organization by Global Knowledge Training LLC
Advised Global Knowledge Training LLC, the largest privately held provider of training and enterprise learning services for information more
Provided legal guidance regarding CERCLA protections and potential liabilities
Provided legal guidance regarding CERCLA protections and potential liabilities associated with the foreclosure of properties contaminated by more